Ignite Creation Date:
2024-05-06 @ 7:21 AM
Last Modification Date:
2024-10-26 @ 11:47 AM
Study NCT ID:
NCT02510378
Status:
UNKNOWN
Last Update Posted:
2015-07-29
First Post:
2015-07-12
Brief Title:
Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases
Sponsor:
Chinese Academy of Medical Sciences
Organization:
ChineseAMS
Study Overview
Official Title:
Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases
Status:
UNKNOWN
Status Verified Date:
2015-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with rectal cancer and resectable liver metastases receive short course radiotherapy5Gyf x 5f to the pelvis and XELOX consolidating chemotherapy al least 4 cycles after 2 weeks
Detailed Description:
Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy with or without target therapy al least 4 cycles after 2 weeks
After evaluation patients with resectable rectal cancer and liver metastasis will undergo surgery Those patients with unresectable lesions will receive chemotherapy
After evaluation patients with resectable rectal cancer and liver metastasis will undergo surgery Those patients with unresectable lesions will receive chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None